

HIV status alters disease severity and immune cell responses in β variant SARS-CoV-2 infection wave

Farina Karim^{1,2} †, Inbal Gazy^{2,3} †, Sandile Cele^{1,2} †, Yenzekile Zungu¹ †, Robert Krause^{1,2} †, Mallory Bernstein¹, Yashica Ganga¹, Hylton Rodel^{1,4}, Ntombifuthi Mthabela¹, Matilda Mazibuko¹, Khadija Khan¹, Daniel Muema^{1,2}, Dirhona Ramjit¹, Thumbi Ndung'u^{1,4,6,7}, Willem Hanekom^{1,4}, Bernadett I. Gosnell⁹, COMMIT-KZN Team[§], Richard Lessells³, Emily Wong^{1,8}, Tulio de Oliveira³, Mahomed-Yunus S. Moosa⁹, Gila Lustig⁵, Alasdair Leslie^{1,4*}, Henrik Kløverpris^{1,4,10*}, Alex Sigal^{1,2,7*}

¹Africa Health Research Institute, Durban 4001, South Africa. ²School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa. ³KwaZulu-Natal Research Innovation and Sequencing Platform, Durban 4001, South Africa. ⁴Division of Infection and Immunity, University College London, London WC1E 6BT, UK. ⁵Centre for the AIDS Programme of Research in South Africa, Durban 4001, South Africa. ⁶HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban 4001, South Africa. ⁷Max Planck Institute for Infection Biology, Berlin 10117, Germany. ⁸Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA. ⁹Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban 4001, South Africa. ¹⁰Department of Immunology and Microbiology, University of Copenhagen, Copenhagen 2200N, Denmark.

† Equal contribution

§ The names/affiliations of COMMIT-KZN Team members not listed separately appear at end of paper

* Corresponding author. Email: al.leslie@ahri.org, henrik.kloverpris@ahri.org, alex.sigal@ahri.org

1 Abstract

2 There are conflicting reports on the effects of HIV on COVID-19. Here we analyzed disease severity and
3 immune cell changes during and after SARS-CoV-2 infection in 236 participants from South Africa, of
4 which 39% were people living with HIV (PLWH), during the first and second (β dominated) infection
5 waves. The second wave had more PLWH requiring supplemental oxygen relative to HIV negative
6 participants. Higher disease severity was associated with low CD4 T cell counts and higher neutrophil to
7 lymphocyte ratios (NLR). Yet, CD4 counts recovered and NLR stabilized after SARS-CoV-2 clearance
8 in wave 2 infected PLWH, arguing for an interaction between SARS-CoV-2 and HIV infection leading to
9 low CD4 and high NLR. The first infection wave, where severity in HIV negative and PLWH was similar,
10 still showed some HIV modulation of SARS-CoV-2 immune responses. Therefore, HIV infection can
11 synergize with the SARS-CoV-2 variant to change COVID-19 outcomes.

12 Introduction

13 HIV is a prevalent infection in KwaZulu-Natal, South Africa [1] which also has a high SARS-CoV-2
14 attack rate [2, 3]. HIV depletes CD4 T helper cells [4] which are a critical part of the adaptive immune
15 response and are also the main target of HIV infection. CD4 T cell death occurs after infection with HIV
16 [5], or in bystander or incompletely infected cells due to activation of cellular defense programs [6, 7], and
17 is halted and, to some extent, reversed by antiretroviral therapy (ART), even sub-optimal therapy [8].

18 The loss of CD4 T cells leads to dysregulation of many aspects of the immune response, including
19 germinal center formation and antibody affinity maturation, which requires help from the highly HIV
20 susceptible CD4 T follicular helper cells [9–11]. In association with this, HIV also causes B cell
21 dysregulation and dysfunction [12]. Moreover, T cell trafficking, activation, and exhaustion profiles of
22 both CD4 and CD8 subsets are also modulated by HIV infection [13–15].

23 Both antibody and T cell responses are critical for effective control and clearance of SARS-CoV-2.
24 More severe COVID-19 disease correlates with lymphopenia and low T cell concentrations [16–18], whilst
25 mild disease correlates with a robust T cell response to SARS-CoV-2 [17, 19–24]. Neutralizing antibodies
26 and associated expansion of antibody secreting B cells (ASC) are elicited in most SARS-CoV-2 infected
27 individuals [25–27], and neutralizing antibody titers strongly correlate with vaccine efficacy [28, 29],
28 indicating their key role in the response to SARS-CoV-2 infection. In contrast, high neutrophil numbers
29 are associated with more severe disease and an elevated neutrophil to lymphocyte ratio (NLR) is often
30 considered a risk factor for a more severe COVID-19 outcome [30–32].

31 Results from epidemiological studies of the interaction between HIV and SARS-CoV-2 from other
32 locations are mixed. Several large studies observed that disease severity and/or mortality risk is increased
33 with HIV infection [33–38] while others found no statistically significant differences in clinical presentation,
34 adverse outcomes, or mortality [39–49]. Worse outcomes for PLWH tended to be in patients with low
35 CD4 [37, 44, 50] and low absolute CD4 count was a risk factor for more severe disease [33].

36 HIV is known to interfere with protective vaccination against multiple pathogens [51–54], typically as
37 a consequence of sub-optimal antibody responses. In line with this, results from a South-African phase
38 I Ib trial of the Novavax NVX-CoV2373 vaccine, which uses a stabilised prefusion spike protein, showed
39 60% efficacy in HIV-uninfected individuals. However, overall efficacy dropped to 49% upon inclusion of
40 PLWH [55], although it is important to note that the numbers of PLWH in the study were very small.
41 Nonetheless, there were more breakthrough cases in PLWH in the vaccine arm than the placebo arm.

42 An important consideration in infections in South Africa is the infecting variant, which in the second
43 infection wave peaking January 2021 was predominantly the B.1.351 variant of concern (VOC) now
44 designated as the β variant. In the current third infection wave it is predominantly the B.1.617.2 δ
45 variant. We and others have shown that the β variant has evolved the ability to escape neutralization
46 by antibody responses elicited by earlier strains of SARS-CoV-2 or by vaccines based on those strains
47 [56–59]. Loss of vaccine efficacy of the AstraZeneca ChAdOx vaccine in South Africa was associated

Table 1: Participant characteristics by HIV status

| | All (n=236) | HIV- (n= 143, 60.6%) | HIV+ (n=93, 39.4%) | Odds Ratio (95% CI) | p-value [#] |
|---------------------------------------|--------------------|-------------------------|-----------------------|------------------------|----------------------|
| Demographics | | | | | |
| Age years, median (IQR) | 45 (35 - 57) | 49 (35 - 62) | 41 (35 - 50) | | 0.003* |
| Male sex, n (%) | 82 (34.7) | 48 (33.6) | 34 (36.6) | 1.1 (0.7 – 2.0) | 0.68 |
| Current smoker, n (%) | 13 (5.51) | 4 (2.8) | 9 (9.7) | 3.7 (1.2 – >10) | 0.038 |
| Comorbidity, n (%) | | | | | |
| Hypertension [§] , n=235 | 57 (24.15) | 42 (29.4) | 15 (16.1) | 0.5 (0.2 – 0.9) | 0.023 |
| Diabetes | 42 (17.8) | 32 (22.4) | 10 (10.8) | 0.4 (0.2 – 0.9) | 0.024 |
| Obesity [§] , n=221 | 91 (42.3) | 64 (47.1) | 27 (29.0) | 0.6 (0.3 – 1.0) | 0.086 |
| Active TB | 10 (4.2) | 1 (0.7) | 9 (9.7) | >10 | 0.001 |
| History TB | 32 (13.6) | 3 (2.1) | 29 (31.2) | >10 | <0.0001 |
| HIV associated parameters | | | | | |
| HIV viremic, n (% of all HIV) | - | - | 28 (30.1) | - | - |
| Years ART, median (IQR) | - | - | 9.4 (3.9 - 13.2) | - | - |
| CD4 cells/μL, median (IQR) n=221 | 633 (326 - 974) | 886.5 (534 - 1148) | 464 (200 - 702) | - | <0.0001* |
| CD4/CD8, median (IQR) n=221 | 1.2 (0.8 – 1.7) | 1.6 (1.2 – 2.1) | 0.8 (0.4 – 1.1) | - | <0.0001* |
| Disease severity, n (%) | | | | | |
| Asymptomatic | 33 (14.0) | 25 (17.5) | 8 (8.6) | 0.4 (0.2 – 1.0) | 0.058 |
| Ambulatory with symptoms | 128 (54.2) | 80 (55.9) | 48 (51.6) | 0.8 (0.5 – 1.4) | 0.59 |
| Supplemental oxygen | 62 (26.3) | 30 (21.0) | 32 (34.4) | 2.0 (1.1 – 3.5) | 0.024 |
| Death | 13 (5.5) | 8 (5.6) | 5 (5.4) | 1.0 (0.3 – 2.9) | >0.99 |
| COVID-19 treatment, n (%) | | | | | |
| Corticosteroids | 74 (31.2) | 47 (32.9) | 27 (29.0) | 0.8 (0.5 – 1.5) | 0.57 |
| Anticoagulants | 53 (22.5) | 35 (24.5) | 18 (19.4) | 0.7 (0.4 – 1.4) | 0.43 |
| Symptom, n (%) | | | | | |
| Sore throat | 88 (37.3) | 55 (38.5) | 33 (35.5) | 0.9 (0.5 – 1.5) | 0.68 |
| Runny nose | 53 (22.5) | 30 (21.0) | 23 (24.7) | 1.2 (0.7 – 2.3) | 0.53 |
| Cough | 153 (64.8) | 91 (63.6) | 62 (66.7) | 1.1 (0.7 – 2.0) | 0.68 |
| History of fever [§] , n=235 | 58 (24.7) | 29 (20.3) | 29 (31.2) | 1.8 (1.0 – 3.3) | 0.063 |
| Shortness of breath | 148 (62.7) | 87 (60.8) | 61 (65.6) | 1.2 (0.7 – 2.1) | 0.49 |

[#] p-value calculated via 2-sided Fisher's Exact test, except for * which was calculated via Mann-Whitney U test. [§]Not including pregnancy or unable to be measured.

48 with this drop in neutralization capacity [60]. The second infection wave driven by β infections also
49 showed increased mortality of hospitalized cases vrelative to the first infection wave [61].

50 What factors contributed to the evolution of the β variant in South Africa is yet unclear. One
51 possibility is intra-host evolution in immunosuppressed PLWH with advanced HIV who are unable to
52 clear SARS-CoV-2 [62]. There is also evidence that variants evolved other adaptations to the host in
53 addition to those in the spike glycoprotein which lead to antibody escape and enhanced transmission.
54 These include evolution of resistance to the host interferon response [63, 64], as well as enhanced
55 cell-to-cell transmission [65]. Changes in the virus may make infection with some variants of concern
56 (VOC) substantially different in disease course, transmission dynamics, and effect on PLWH relative to
57 ancestral SARS-CoV-2 strains or possibly other variants.

58 Here we aimed to determine the effects of HIV on the immune response to SARS-CoV-2 infection
59 in KwaZulu-Natal, South Africa. This is important because we need to better understand COVID-19
60 disease course and vaccine efficacy in this population, as well as the possible reasons for the emergence of
61 the currently circulating variants which lead to immune escape from neutralizing antibodies. Our results
62 indicate that infections in the β variant infection wave led to more severe disease in PLWH relative to
63 HIV negative participants. Higher severity was associated with a lower CD4 T cell count. Yet, the CD4
64 count recovered, indicating that these participants may not have had a low CD4 count when first exposed
65 to SARS-CoV-2. In addition, there were changes in the response of immune cell subsets associated with
66 SARS-CoV-2 infection in PLWH relative to HIV negative participants in the first infection wave, even in
67 the absence of a statistically significant increase in disease severity, indicating that HIV infection may
68 modulate the immune response to SARS-CoV-2.

69 Results

70 HIV infection is associated with higher disease severity in the β variant infection wave

71 We initiated a longitudinal observational cohort study to enroll and track patients with a positive
72 COVID-19 qPCR test presenting at three hospitals in Durban, South Africa. Patients presented due to
73 either COVID-19 symptoms or because they were known contacts of a confirmed COVID-19 case.




Figure 1: Differences in PLWH COVID-19 outcome and ART suppression between waves. (A) Fraction of PLWH and HIV negative participants requiring supplemental oxygen during the first and the β VOC dominated second infection waves in South Africa. $p=0.0025$ by Fisher's Exact test. (B) Frequency of HIV viremia in wave 1 versus wave 2. Frequency was calculated as the number of study timepoints in wave 1 or wave 2 with HIV RNA > 200 copies/ml divided by all measured timepoints for PLWH. (C) The fraction of timepoints with no detectable ART in wave 1 versus wave 2. Fraction was calculated as the number of study timepoints in wave 1 or wave 2 where the concentration of none of the ART components was above level of quantification divided by all measured PLWH timepoints. p -values are * <0.05 ; ** <0.01 ; *** < 0.001 , **** < 0.0001 as determined by Fisher's Exact test.

74 All participants were initially admitted to a hospital facility, then discharged after varying periods
75 and followed up as outpatients. Enrollment was between June 2020 and May 2021. Participants were
76 followed up weekly for the first month post-enrollment, and at 3 month intervals thereafter. At each
77 study visit, a blood sample and a combined nasopharyngeal and oropharyngeal swab was taken. The
78 purpose of a combined swab was to maximize the detection probability by qPCR of SARS-CoV-2 in
79 the upper respiratory tract. Blood was used to determine HIV status, HIV viral load, and cellular
80 parameters such as the concentration of CD4 T cells and the neutrophil to lymphocyte ratio. We also
81 tested the frequencies more specific immune cell subsets by flow cytometry (only available for infection
82 wave 1 samples).

83 Up to May 2021, 236 participants were enrolled in the study, for a total of 986 study visits (Sup-
84 plementary File 1). All participants are assumed to be vaccinated with BCG in infancy in accordance
85 with South African national guidelines. The majority of participants were female, possibly reflecting
86 better linkage to care. Enrollment was a median 11 days post-symptom onset (Supplementary File 2).
87 De-identified participant data used here are available as a Source Data 1 included in the supplementary
88 materials.

89 Out of 236 study participants, 93 (39%) were PLWH (Table 1) and 89% of study participant were
90 of African descent. PLWH were significantly younger than HIV uninfected participants. Hypertension,
91 diabetes and obesity, known risk factors for more severe COVID-19 disease [47, 66], were common:
92 Hypertension and obesity were present in 24%, and 42% of study participants respectively, a similar
93 prevalence to that reported in the province of KwaZulu-Natal where this study was performed [67, 68].
94 Diabetes prevalence in our study was 18%, compared to 13% reported for South Africa [69]. Hypertension
95 and diabetes were significantly lower in the PLWH group (Table 1). 28 or 30% of PLWH were HIV
96 viremic at any point in the study. For individuals on ART, median ART duration was 9 years. ART
97 regimen was determined by liquid chromatography with tandem mass spectrometry (LC-MS-MS) and
98 was predominately efavirenz (EFV) based, with some participants transitioning to a dolutegravir (DTG)
99 based regimen. In addition, there was a small subset of PLWH on a ritonavir boosted lopinavir (LPV/r)
100 as well as other ART combinations and about 12% of PLWH had no detectable ART despite a clinical
101 record of ART, or were ART naive (Supplementary File 3). The absolute CD4 T cell count and the CD4
102 to CD8 T cell ratio was significantly lower in PLWH relative to HIV negative participants at enrollment.
103 The incidence of active TB and the fraction of participants with a history of TB were much higher in
104 the PLWH group (Table 1).

105 A minority of study participants (14%) were asymptomatic and presented at the hospital because of a
106 close contact with a confirmed COVID-19 case. To include the asymptomatic participants in our analysis,
107 we used time from diagnostic swab as our timescale, which was tightly distributed for symptomatic
108 participants relative to symptom onset at a median of 3 to 4 days apart (Supplementary File 2).

109 The majority of participants in the study (54%) had symptoms but did not progress beyond mild
110 disease, defined here as not requiring supplemental oxygen during the course of disease and convalescence.
111 26% of participants required supplemental oxygen but did not die and 6% of participants died. Our
112 cohort design did not specifically enroll critical SARS-CoV-2 cases. The requirement for supplemental
113 oxygen, as opposed to death, was therefore our primary measure for disease severity.

114 There was a significant difference in the frequency of participants requiring supplemental oxygen
115 (without subsequent death) between HIV negative participants and PLWH (21% versus 34% respectively,
116 odds ratio of 2.0 with 95% confidence intervals of 1.1-3.5, Table 1).

117 To determine if the fraction of participants requiring supplemental oxygen differed between the
118 first infection wave and the β variant dominated second infection wave, we compared disease severity
119 between the first infection wave (Figure 1, Supplementary File 4), and the second infection wave
120 (Figure 1, Supplementary File 5). In the first infection wave, there was no significant difference in the
121 fraction of participants requiring supplemental oxygen between HIV negative and PLWH participants
122 (Supplementary File 4, $p=0.5$). However, significantly more PLWH required supplemental oxygen in the
123 second wave (Supplementary File 5, odds ratio of 4.0 with 95% CI of 1.6-10.4, $p=0.005$). Comparing
124 within the HIV negative and PLWH groups, there was only a moderate increase in the fraction of
125 participants requiring supplemental oxygen between SARS-CoV-2 infection wave 1 and infection wave
126 2 in HIV negative participants (19% to 25%) which was not significant (Figure 1A). In contrast, the

Table 2: Characteristics by HIV status of participants requiring supplemental oxygen

| | All (n=68) | HIV- (n= 35, 51.5%) | HIV+ (n=33, 48.5%) | Odds Ratio (95% CI) | p-value [#] |
|--|------------------|------------------------|-----------------------|------------------------|----------------------|
| Demographics | | | | | |
| Age years, median (IQR) | 50.5 (38 – 63.5) | 62 (47 - 66) | 41 (36 - 56) | - | 0.003* |
| Male sex, n (%) | 25 (36.8) | 12 (34.3) | 13 (39.4) | 1.2 (0.5 – 3.3) | 0.80 |
| Current smoker, n (%) | 2 (2.9) | 1 (2.9) | 1 (3.0) | 1.1 (<0.1 – >10) | >0.99 |
| Comorbidity, n (%) | | | | | |
| Hypertension | 26 (38.2) | 18 (51.4) | 8 (24.2) | 0.3 (0.1 – 0.8) | 0.026 |
| Diabetes | 17 (25.0) | 13 (37.1) | 4 (12.1) | 0.2 (0.1 – 0.8) | 0.025 |
| Obesity [§] , n= 57 | 23 (40.4) | 11 (31.4) | 12 (36.4) | 1.8 (0.6 – 5.1) | 0.42 |
| Active TB | 6 (8.8) | 1 (2.9) | 5 (15.2) | 6.1 (0.9 – >10) | 0.10 |
| History TB | 16 (23.5) | 2 (5.7) | 14 (42.4) | 12.2 (2.7 – >10) | <0.001 |
| HIV associated parameters | | | | | |
| HIV viremic, n (% of all HIV) | - | - | 9 (27.3) | - | - |
| Years ART, median (IQR) | - | - | 11.6 (6.1 – 13.3) | - | - |
| CD4 cells/ μ L, median (IQR) n=65 | 309 (170 - 545) | 339 (227 - 592) | 277 (134 – 461) | - | 0.072* |
| COVID-19 treatment, n (%) | | | | | |
| Corticosteroids | 43 (63.2) | 25 (71.4) | 18 (54.5) | 0.5 (0.2 – 1.3) | 0.21 |
| Anticoagulants | 31 (45.6) | 18 (51.4) | 13 (39.4) | 0.6 (0.2 – 1.6) | 0.34 |

[#] p-value calculated via 2-sided Fisher's Exact test, except for * which was calculated via Mann-Whitney U test. [§]Not including pregnancy or unable to measure.

127 number of PLWH participants requiring supplemental oxygen more than doubled from 24% to 57%
128 (p=0.0025, Figure 1A).

129 To examine whether the differences in the requirement for supplemental oxygen in PLWH were
130 because of differences in the level of HIV control between waves, we examined the fraction of timepoints
131 where participants showed HIV viremia (we excluded low level viremia of unclear significance and set the
132 threshold at VL_t≥200 copies/ml [70]). Furthermore, we determined whether ART was detectable in the
133 blood by LC-MS/MS. Second wave participants had approximately 2-fold higher fraction of timepoints
134 where HIV viremia was detected (Figure 1B). In agreement with this, the fraction of participants with no
135 detectable ART in the blood was also about 2-fold higher (Figure 1C). These observations are consistent
136 with diminished suppression of HIV in second wave PLWH enrolled in this study. The specific HIV
137 regimen had no discernible effect on disease severity (Figure 1-figure supplement 1).

138 We compared comorbidities and other characteristics between the PLWH and HIV negative par-
139 ticipants on supplemental oxygen (Table 2). Strikingly, the median age of PLWH on supplemental
140 oxygen was 21 years younger relative to HIV negative (41 versus 62, p=0.003). PLWH had significantly
141 lower frequency of comorbidities which are usually associated with more severe COVID-19 disease: both
142 hypertension (p=0.03) and diabetes (p=0.03) were lower. In contrast, the median CD4 T cell count across
143 all study visits was lower in PLWH (277 versus 339) although this difference did not reach statistical
144 significance (p=0.07). There was no significant difference in the fraction of participants treated with
145 corticosteroids (p=0.2).

146 Interestingly, when comparing HIV negative participants requiring supplemental oxygen to those

147 with not requiring supplemental oxygen (Supplementary File 6), those on supplemental oxygen were
148 significantly older (62 versus 47 years, $p=0.002$), and had significantly higher frequency of hypertension
149 ($p=0.002$) and diabetes ($p=0.02$). This differed from PLWH, where differences in age and comorbidities
150 were not significant between PLWH requiring supplemental oxygen and those not (Supplementary File
151 7), although there was a trend to a higher frequency for hypertension ($p=0.1$).

152 HIV viremic participants showed lower CD4 counts relative to HIV suppressed or HIV negative
153 participants (Figure 1-figure supplement 2). Surprisingly, there was no difference in either the fraction of
154 HIV viremic timepoints or fraction of timepoints where ART was not detected in the blood between
155 the supplemental oxygen and no supplemental oxygen groups (Figure 1-figure supplement 3). We also
156 analyzed the time of SARS-CoV-2 clearance as a function of CD4 count and HIV status and found
157 that while a participants with a low CD4 count (< 200) showed a trend of longer time to SARS-CoV-2
158 clearance ($p=0.11$), HIV viremia had no effect (Figure 1-figure supplement 4). Hence, while the PLWH
159 enrolled in the second wave had both worse control of HIV infection and had a higher fraction requiring
160 supplemental oxygen, we did not observe that the PLWH requiring supplemental oxygen had a higher
161 frequency of HIV viremia.

162 **SARS-CoV-2 has differential effects on CD4 count and the neutrophil to lymphocyte ratio** 163 **between infection waves in PLWH**

164 We next determined whether the increased disease severity in PLWH in infection wave 2 was reflected
165 in the cellular immune response to SARS-CoV-2 infection. We therefore examined the CD4 count and
166 NLR, both known to be strongly associated with disease severity. We used a 3-point scale for disease
167 severity, where 1: asymptomatic, 2: mild, and 3: supplemental oxygen (at any point in the study) or
168 death. Death was merged with supplemental oxygen because of the small number of participants who
169 died, and was not excluded in any of the subsequent analyses.

170 As expected, we observed a significant decrease in CD4 T cell count at the highest severity which
171 included disease that required administration of supplemental oxygen and/or resulted in death (Figure
172 2A, see Figure 2-figure supplement 1 for all data points and number of data points per graph).

173 We then asked whether PLWH in infection wave 2 showed different CD4 responses to SARS-CoV-2.
174 Since decreased CD4 count could be due to HIV infection alone, we separated the data into timepoints
175 when SARS-CoV-2 was detectable by qPCR and after it was cleared. Upon SARS-CoV-2 clearance, the
176 immune response of convalescent participants should start the return to baseline, and differences due to
177 SARS-CoV-2 should decrease and reflect HIV mediated effects only.

178 The CD4 counts in PLWH in infection wave 2 were lower during active SARS-CoV-2 infection relative
179 to wave 1 (Figure 2B, median 172 versus 420 cells/ μL , a decrease of 2.4-fold) and were below the 200
180 cells/ μL clinically used threshold indicating a low CD4 count. However, CD4 counts for PLWH for
181 both wave 2 and wave 1 recovered post-SARS-CoV-2 clearance (408 for wave 2 versus 584 cells/ μL for
182 wave 1), consistent the low CD4 count in PLWH in wave 2 being SARS-CoV-2 induced. CD4 counts
183 for both groups were substantially above the 200 cells/ μL threshold after SARS-CoV-2 clearance. HIV
184 negative participants showed no or minor differences in CD4 counts between waves, although these minor
185 differences showed significance due to the large number of participant timepoints for this group (Figure
186 2C).




Figure 2: The differential effect of HIV on the CD4 count and neutrophil to lymphocyte ratio between waves. (A) The concentration of CD4 T cells in the blood in all participants in all infection waves and at all timepoints as a function of disease severity. Disease severity was scored as 1: asymptomatic, 2: mild, and 3: on supplemental oxygen or death. CD4 counts in PLWH (B) and HIV negative (C) participants in waves 1 versus waves 2 during active SARS-CoV-2 infection and after SARS-CoV-2 clearance. (D) Neutrophil to lymphocyte ratio (NLR) in the blood in all participants in all infection waves and at all timepoints as a function of disease severity. NLR in PLWH (E) and HIV negative (F) participants in waves 1 versus waves 2 during active SARS-CoV-2 infection and after SARS-CoV-2 clearance. SARS-CoV-2 positive indicates a timepoint where SARS-CoV-2 RNA was detected. Data shown as violin plots with median and IQR, with the median denoted below each plot. Fold-change in the second wave versus first wave is indicated, with arrow denoting direction of change. p-values are * <math><0.05</math>; ** <math><0.01</math>; *** <math><0.001</math>, **** <math><0.0001</math> as determined by Kruskal-Wallis test with Dunn's multiple comparison correction or by Mann-Whitney U test. Plots scales were restricted to highlight changes close to the median. See Fig.S6 for complete plots and the number of data points per plot.

187 The NLR had a remarkably similar pattern. An elevated NLR associated strongly with higher disease
 188 severity (Figure 2D). PLWH with active SARS-CoV-2 infection in wave 2 showed a 2-fold increase in the
 189 NLR relative to PLWH with active SARS-CoV-2 infection in wave 1 (Figure 2E). This difference declined
 190 to 1.2-fold once SARS-CoV-2 was cleared, consistent with differences in NLR being SARS-CoV-2 driven
 191 and not a result of other pathology in PLWH in wave 2. In contrast, the NLR was lower in HIV negative
 192 participants in wave 2 relative to wave 1 in the presence of SARS-CoV-2 (Figure 2F).

193 The observed recovery of the CD4 count may result from improved access to ART due to the hospital
 194 visit in wave 2. We therefore checked whether the fraction of HIV viremic participants decreased upon
 195 convalescence and whether there was an associated decrease in the number of PLWH with undetectable
 196 ART. We observed no significant differences in either viremia or fraction of PLWH with undetectable
 197 ART in either wave between timepoints which were SARS-CoV-2 positive and those that were negative
 198 (Figure 2-figure supplement 2). This indicates that the increase in the CD4 was not due to better linkage
 199 to care after the hospital visit but rather due to SARS-CoV-2 clearance.

200 **Differences in the frequencies and associations of immune cell subsets in PLWH and HIV**
 201 **negative participants**

202 To examine differences in immune cell subset associations between HIV negative and PLWH participant
 203 groups, we conducted detailed phenotyping of immune cells using longitudinal fresh PBMC samples
 204 and correlated these to measured phenotypes and clinical parameters in both HIV negative and PLWH
 205 groups (Figure 3; see Figure 3-figure supplement 1 for gating strategies). We used established approaches
 206 for gating of cell subsets [71] and [72]. This was only performed for the first wave participants, where
 207 cells were available for additional phenotyping by flow cytometry.




Figure 3: Immune cell and clinical correlates in HIV negative and PLWH groups. Spearman rank correlation values (ρ) are shown from red (1.0) to blue (-1.0). p-values per correlation are * < 0.5; ** < 0.01; *** < 0.001. The number of matched pairs for HIV negative participants ranged from 77 to 229 and for PLWH from 48 to 164. Rectangles represent regions where a set of correlations is present in one group and absent in the other. Black dashed lines represent the divide between clinical and cellular parameters.

208 For HIV negative participants, there were significant negative and positive correlations between CD4
 209 T cell parameters, and between these and the CD8 T cell count and phenotypes (Figure 3, yellow box).
 210 There were negative correlations between CD4 and the CD8 CCR7+ T cell phenotype and CD56+CD16+
 211 NK cells (purple box). The fraction of NK cells positively correlated with the CXCR3 fraction of CD4
 212 T cells, with HLA-DR on CD8 T cells, and with PD-1 on both cell types (purple box). In addition,
 213 there were correlations between CD8 T cell count and CD19 B cell parameters, such as fractions of
 214 naïve and memory B cells (red box). Interestingly, disease severity as well as the CD4/CD8 ratio showed
 215 correlations with B cell parameters, including the frequency of antibody secreting cells (ASC), which
 216 were lost in PLWH (orange box).

217 New correlations arose in PLWH, particularly involving CD8 T cells: CXCR3+ CD8 T cells were
 218 negatively correlated with disease severity but positively correlated with the CD4/CD8 ratio and the
 219 CD4 T cell count (Figure 3, black box). CD8 T cell activation (HLA-DR+) was correlated with several
 220 CD19+ B cell phenotypes (green box), and the plasma cell to plasmablast ratio, determined by CD138
 221 expression, correlated with both CD4 and CD8 T cell phenotypes (blue box). In addition, CD8 T cell
 222 count showed negative correlations with CD8 PD-1 and NK cell phenotypes only in PLWH (turquoise

223 box).

224 Out of the set of markers examined, the combination of PD-1 and HLA-DR expression is linked to
225 T cell activation [73, 74], while CXCR3 expression is essential to recruitment of T cells to tissues [75].
226 We therefore asked whether these markers showed differences between HIV negative and PLWH in the
227 first infection wave during the time participants were positive for SARS-CoV-2, despite there being no
228 significant differences in disease severity in this wave. In CD8 T cells, we observed a significant decrease
229 in the fraction of CXCR3 expressing cells in the blood compartment in PLWH relative to HIV negative
230 participants (Figure 4A). We also observed an increase in the fraction of PD-1+HLA-DR+ cells (Figure
231 4B). For CD4 cells, there was no significant decrease in the fraction of CXCR3+ cells although a decrease
232 was apparent (Figure 4C). Similarly to CD8 T cells, there was an increase in PD-1+HLA-DR+ CD4 T
233 cells in PLWH (Figure 4D). There was no difference between PLWH and HIV negative participants in
234 any cell/marker combination after SARS-CoV-2 clearance.




Figure 4: Differences between PLWH and HIV negative participants in immune cell markers. Percent of CD8 T cells positive for CXCR3 (A) or double positive for HLA-DR and PD-1 (B). Percent of CD4 T cells positive for CXCR3 (C) or double positive for HLA-DR and PD-1 (D). Data is composed of 15 participant timepoints which were SARS-CoV-2+HIV-, 14 SARS-CoV-2+HIV+, 40 SARS-CoV-2-HIV+ and 74 SARS-CoV-2-HIV-, where SARS-CoV-2+ indicates SARS-CoV-2 RNA was detected in the upper respiratory tract. p-values for differences between PLWH and HIV negative participants are * < 0.05; ** < 0.01; *** < 0.001, **** < 0.0001 as determined by the Mann-Whitney U test.

235 Discussion

236 We observed that in our cohort, COVID-19 disease severity was higher in PLWH, consistent with some
237 of the larger epidemiological studies [33–38], although in this study differences were detected in the
238 frequency of participants requiring supplemental oxygen and not in mortality. Our cohort may not be a
239 typical 'hospitalized cohort' as the majority of participants did not require supplemental oxygen. We
240 therefore cannot discern effects of HIV on critical SARS-CoV-2 cases since these numbers are too small in
241 the cohort. However, focusing on lower disease severity enabled us to capture a broader range of outcomes
242 which predominantly ranged from asymptomatic to requiring supplemental oxygen. Understanding this
243 part of the disease spectrum could be important since it may indicate underlying changes in the immune
244 response which affect long-term quality of life and response to vaccines.

245 A higher fraction of PLWH requiring supplemental oxygen relative to HIV negative participants was
246 driven by SARS-CoV-2 infections in the second, β variant dominated SARS-CoV-2 infection wave in
247 South Africa. The odds ratio for requiring supplemental oxygen in the second wave for PLWH was 4.0
248 relative to HIV negative participants. The 95% confidence intervals were wide at 1.6-10.4, reflecting the
249 relatively small number of participants. However, confidence intervals did not overlap one.

250 Consistent with HIV infection leading to more severe SARS-CoV-2 infection outcomes in our study is
251 the much younger age of PLWH requiring supplemental oxygen relative to HIV negative participants
252 (41 versus 63 years). PLWH on supplemental oxygen also had lower frequencies of hypertension and
253 diabetes. Age, hypertension, and diabetes are risk factors for more severe COVID-19 disease [38, 76–78],
254 and their absence may indicate that the more severe outcome is driven by another factor, with HIV
255 infection being the simplest explanation.

256 The cause of the difference between waves in PLWH may be because PLWH enrolled in the second
257 infection wave had worse suppression of HIV with ART: both the fractions of timepoints where viremia
258 was detected and where ART was absent were about 2-fold higher and indeed were very high at about
259 40%. We therefore expected that this showed a direct link between HIV viremia and the requirement
260 for supplemental oxygen during COVID-19 disease in PLWH. However, there was no difference in the
261 frequency of viremia between those requiring supplemental oxygen and those not.

262 Furthermore, the substantial recovery of CD4 T cell counts in PLWH after SARS-CoV-2 clearance
263 in wave 2 may be consistent with the β variant having more impact on the CD4 count relative to the
264 ancestral SARS-CoV-2 strain infections in the first wave. A similar pattern was seen in the NLR, which
265 was higher in wave 2 relative to wave 1 in PLWH with active SARS-CoV-2 infection, but then decreased
266 to similar levels upon convalescence. The role of the β variant is supported by data showing extensive
267 evolution, increasing the ability of β to escape the interferon response and result in more efficient viral
268 cell-to-cell transmission [63–65]. β variant hospitalizations also led to more deaths in South Africa [61].
269 Therefore, the effect of the variant on PLWH in addition to HIV suppression status should be considered.

270 Our data detailing the SARS-CoV-2 response of more defined immune cell subsets in PLWH versus
271 HIV negative participants is limited by the data only being available for the first infection wave. However,
272 even in samples from that wave, there were multiple differences in correlations between cell subsets
273 in PLWH relative to HIV negative participants, which may be another indication of differences in the
274 immune response to SARS-CoV-2. We cannot deduce from these associations whether the differences
275 could have an impact on disease severity. However, the fraction of CXCR3+ CD8 T cells decreased in the
276 blood compartment and PD-1+HLA-DR+ CD8 and CD4 T cells increased. The increase in PD-1+HLA-
277 DR+ T cells indicates T cell activation [73, 74] which associates with worse COVID-19 outcomes [79].
278 CXCR3 plays a key role in T cell homing to sites of inflammation and is activated by interferon-inducible
279 ligands CXCL9, CXCL11, and CXCL10 (IP-10) [75, 80]. A decrease in CXCR3 indicates either that T
280 cells are less able to home to the site of infection, or that there is more inflammation in PLWH during
281 SARS-CoV-2 infection and therefore more homing of the CXCR3+ CD8 T cells to tissues so that the
282 fraction of CXCR3+ cells left in the blood decreases. Either way, the combination of these changes likely
283 indicates either more pronounced SARS-CoV-2 infection or an impaired response in PLWH despite the
284 similar infection outcomes in this wave.

285 In summary, PLWH showed increased disease severity mostly restricted to the second infection wave,
286 where the β variant was dominant. Increased severity was associated with low CD4 T cell counts and
287 high NLR which stabilized post-SARS-CoV-2 clearance in second wave infected PLWH to close to wave 1
288 PLWH values, arguing for a synergy between SARS-CoV-2 and HIV to decrease CD4 T cell numbers and
289 increase the NLR rather than the status of HIV infection alone determining these parameters. More work
290 is required to understand how these HIV related immune perturbations influence long-term immunity to
291 SARS-CoV-2 infection and whether vaccine response will be affected.

292 **Material and Methods**

293 **Ethical statement and study participants**

294 The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board
295 (approval BREC/00001275/2020). Adult patients (>18 years old) presenting at King Edward VIII, Inkosi
296 Albert Luthuli Central, or Clairwood Hospitals in Durban, South Africa, between 8 June to 25 September
297 2020, diagnosed to be SARS-CoV-2 positive as part of their clinical workup and able to provide informed
298 consent were eligible for the study. Written informed consent was obtained for all enrolled participants.

299 **Clinical laboratory testing**

300 An HIV rapid test and viral load quantification was performed from a 4ml EDTA tube of blood at
301 an accredited diagnostic laboratory (Molecular Diagnostic Services, Durban, South Africa) using the
302 RealTime HIV negative1 viral load test on an Abbott machine. CD4 count, CD8 count, and a full blood
303 count panel were performed by an accredited diagnostic laboratory (Ampath, Durban, South Africa).
304 Depending on the volume of blood which was drawn, the CD8, CD4, and full blood count was not
305 available for every participant, and numbers performed are detailed in the figure legends.

306 **qPCR detection of SARS-CoV-2**

307 RNA was extracted from combined oropharyngeal and nasopharyngeal swabs from 140 μ l viral transport
308 medium using the QIAamp Viral RNA Mini kit (cat. no. 52906, QIAGEN, Hilden, Germany) according
309 to manufacturer's instructions, and eluted into 100 μ l AVE buffer. To detect SARS-CoV-2 RNA, 5 μ l
310 RNA was added to the TaqPath 1-step RT-qPCR mastermix. 3 SARS-CoV-2 genes (ORF1ab, S and N)
311 were amplified using the TaqPath COVID-19 Combo Kit and TaqPath COVID-19 CE-IVD RT-PCR Kit
312 (ThermoFisher Scientific, Massachusetts, United States) in a QuantStudio 7 Flex Real-Time PCR system
313 (ThermoFisher Scientific). Data was analysed using the Design and Analysis software (ThermoFisher
314 Scientific). For positive samples, Ct values are represented as the average of the Ct values of all three
315 genes. A sample was scored positive where at least 2 out of the 3 genes were detected, and inconclusive
316 if only 1 of the genes was detected.

317 **PBMC isolation and immune phenotyping by flow cytometry**

318 PBMCs were isolated by density gradient centrifugation using Histopaque 1077 (Sigma-Aldrich, St.
319 Louis, Missouri, United States) and SepMate separation tubes (STEMCELL Technologies, Vancouver,
320 Canada). For T cell and NK cell phenotyping, 10^6 fresh PBMCs were surface stained in 50l antibody
321 mix with the following antibodies from BD Biosciences (Franklin Lakes, NJ, USA): anti-CD45 Hv500
322 (1:100 dilution, clone HI30, cat. 560777); anti-CD8 BV395 (1:50 dilution, clone RPA-T8, cat. 563795);
323 anti-CD4 BV496 (1:25 dilution, clone SK3, cat. 564651); anti-PD1 BV421 (1:50 dilution, clone EH12.1,
324 cat. 562516); anti-CXCR3 PE-CF594 (1:25 dilution, clone 1C6/CXCR3, cat. 562451). The following
325 antibodies were from BioLegend (San Diego, CA, USA): anti-CD19 Bv605 (1:100 dilution, clone HIB19,
326 cat. 302244); anti-CD16 Bv650 (1:50 dilution, clone 3G8, cat. 302042); anti-CD56 Bv711 (1:50 dilution,
327 clone HCD56, cat. 318336); anti-CD3 Bv785 (1:25 dilution, clone OKT3, cat. 317330); anti-CXCR5
328 FITC (1:25 dilution, clone J252D4, cat. 356914); anti-HLA-DR PE (1:50 dilution, clone L243, cat.
329 307606); anti-CCR7 PerCP-Cy5.5 (1:25 dilution, clone G043H7, cat. 353220); anti-CD38 PE-Cy7 (1:25
330 dilution, clone HIT2, cat. 303516); anti-ICOS APC (1:25 dilution, clone C398.4A, cat. 313510) and
331 anti-CD45RA AF700 (1:25 dilution, clone HI100, cat. 304120). PBMCs were incubated with antibodies
332 for 20 minutes at room temperature. For B-cell phenotyping, the following antibodies were used: (all
333 from BioLegend) anti-CD45 APC (1:25 dilution, clone HI30, cat. 304012); anti-CD3 Bv711 (1:50 dilution,
334 clone OKT3, cat. 317328), anti-CD14 Bv711 (1:25 dilution, clone M5E2, cat. 301838); anti-CD19 Bv605
335 (1:50 dilution, clone HIB19, cat. 302244); anti-CD27 Hv500 (1:50 dilution, clone O323, cat. 302836);
336 anti-CD38 PE-Cy7 (1:25 dilution, clone HIT2, cat. 303516) and anti-CD138 BV785 (1:25 dilution,
337 clone MI15, cat. 356538). Cells were then washed twice in PBS and fixed in 2% paraformaldehyde and

338 stored at 4°C before acquisition on FACSria Fusion III flow cytometer (BD) and analysed with FlowJo
339 software version 9.9.6 (Tree Star). Depending on the volume of blood which was drawn, full phenotyping
340 was only available for participants where sufficient blood was available for the assay.

341 **Statistical analysis**

342 Data is described with the non-parametric measures of median and interquartile range, and significance
343 determined using the non-parametric Mann-Whitney U test for pairwise comparisons, Fisher Exact test
344 for pairwise comparisons of frequencies, and the Kruskal-Wallis test with multiple comparison correction
345 by the Dunn Method for comparisons involved more than two populations. All tests were performed
346 using Graphpad Prism 8 or Stata software.

347 **Acknowledgements**

348 This work was supported by the Bill and Melinda Gates Investment INV-018944 to AS.

349 **COMMIT-KZN Team**

350 Moherndran Archary, Department of Paediatrics and Child Health, University of KwaZulu-Natal
351 Kaylesh J. Dullabh, Department of Cardiothoracic Surgery, University of KwaZulu-Natal
352 Jennifer Giandhari, KwaZulu-Natal Research Innovation and Sequencing Platform
353 Philip Goulder, Africa Health Research Institute and Department of Paediatrics, Oxford
354 Guy Harling, Africa Health Research Institute and the Institute for Global Health, University College
355 London
356 Rohen Harrichandparsad, Department of Neurosurgery, University of KwaZulu-Natal
357 Kobus Herbst, Africa Health Research Institute and the South African Population Research Infrastructure
358 Network
359 Prakash Jeena, Department of Paediatrics and Child Health, University of KwaZulu-Natal
360 Thandeka Khoza, Africa Health Research Institute
361 Nigel Klein, Africa Health Research Institute and the Institute of Child Health, University College
362 London
363 Richard Lessells, KwaZulu-Natal Research Innovation and Sequencing Platform
364 Rajhmun Madansein, Department of Cardiothoracic Surgery, University of KwaZulu-Natal
365 Mohlopheni Marakalala, Africa Health Research Institute and Division of Infection and Immunity,
366 University College London
367 Mosa Moshabela, College of Health Sciences, University of KwaZulu-Natal
368 Kogie Naidoo, Centre for the AIDS Programme of Research in South Africa
369 Zaza Ndhlovu, Africa Health Research Institute and the Ragon Institute of MGH, MIT and Harvard
370 Kennedy Nyamande, Department of Pulmonology and Critical Care, University of KwaZulu-Natal
371 Nesri Padayatchi, Centre for the AIDS Programme of Research in South Africa
372 Vinod Patel, Department of Neurology, University of KwaZulu-Natal
373 Theresa Smit, Africa Health Research Institute
374 Adrie Steyn, Africa Health Research Institute and Division of Infectious Diseases, University of Alabama
375 at Birmingham

376 **References**

- 377 1. Kharsany, A. B., Cawood, C., Khanyile, D., Lewis, L., Grobler, A., Puren, A., Govender, K.,
378 George, G., Beckett, S. & Samsunder, N. Community-based HIV prevalence in KwaZulu-Natal,
379 South Africa: results of a cross-sectional household survey. *The Lancet HIV* **5**, e427–e437. ISSN:
380 2352-3018 (2018).

- 381 2. Tegally, H., Wilkinson, E., Lessells, R. R., Giandhari, J., Pillay, S., Msomi, N., Mlisana, K., Bhiman,
382 J., Allam, M., Ismail, A., Engelbrecht, S., Van Zyl, G., Preiser, W., Williamson, C., Petruccione,
383 F., Sigal, A., Gazy, I., Hardie, D., Hsiao, M., Martin, D., York, D., Goedhals, D., San, E. J.,
384 Giovanetti, M., Lourenco, J., Alcantara, L. C. J. & de Oliveira, T. Major new lineages of SARS-
385 CoV-2 emerge and spread in South Africa during lockdown. *medRxiv*, 2020.10.28.20221143. <https://www.medrxiv.org/content/medrxiv/early/2020/10/30/2020.10.28.20221143.full.pdf>
386 (2020).
387
- 388 3. Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D.,
389 Pillay, S., San, E. J., Msomi, N., Mlisana, K., von Gottberg, A., Walaza, S., Allam, M., Ismail, A.,
390 Mohale, T., Glass, A. J., Engelbrecht, S., Van Zyl, G., Preiser, W., Petruccione, F., Sigal, A.,
391 Hardie, D., Marais, G., Hsiao, M., Korsman, S., Davies, M.-A., Tyers, L., Mudau, I., York, D.,
392 Maslo, C., Goedhals, D., Abrahams, S., Laguda-Akingba, O., Alisoltani-Dehkordi, A., Godzik,
393 A., Wibmer, C. K., Sewell, B. T., Lourenço, J., Alcantara, L. C. J., Pond, S. L. K., Weaver,
394 S., Martin, D., Lessells, R. J., Bhiman, J. N., Williamson, C. & de Oliveira, T. Emergence and
395 rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2)
396 lineage with multiple spike mutations in South Africa. *medRxiv*, 2020.12.21.20248640. <https://www.medrxiv.org/content/medrxiv/early/2020/12/22/2020.12.21.20248640.full.pdf>
397 (2020).
398
- 399 4. Dalglish, A. G., Beverley, P. C., Clapham, P. R., Crawford, D. H., Greaves, M. F. & Weiss, R. A.
400 The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature*
401 **312**, 763–767 (1984).
- 402 5. Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debating,
403 K.-M. & Krammer, P. H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and
404 gp120. *Nature* **375**, 497–500 (1995).
- 405 6. Doitsh, G., Cavrois, M., Lassen, K. G., Zepeda, O., Yang, Z., Santiago, M. L., Hebbeler, A. M.
406 & Greene, W. C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in
407 human lymphoid tissue. *Cell* **143**, 789–801. ISSN: 1097-4172 (Electronic) 0092-8674 (Linking).
408 <http://www.ncbi.nlm.nih.gov/pubmed/21111238> (2010).
- 409 7. Doitsh, G., Galloway, N. L., Geng, X., Yang, Z., Monroe, K. M., Zepeda, O., Hunt, P. W., Hatano,
410 H., Sowinski, S., Munoz-Arias, I. & Greene, W. C. Cell death by pyroptosis drives CD4 T-cell
411 depletion in HIV-1 infection. *Nature* **505**, 509–14. ISSN: 1476-4687 (Electronic) 0028-0836 (Linking).
412 <http://www.ncbi.nlm.nih.gov/pubmed/24356306> (2014).
- 413 8. Jackson, L., Hunter, J., Cele, S., Ferreira, I. M., Young, A. C., Karim, F., Madansein, R., Dullabh,
414 K. J., Chen, C.-Y., Buckels, N. J., Ganga, Y., Khan, K., Boule, M., Lustig, G., Neher, R. A. &
415 Sigal, A. Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by
416 reducing cell death. *eLife* **7**, e30134 (2018).
- 417 9. Okoye, A. A. & Picker, L. J. CD 4+ T-cell depletion in HIV infection: mechanisms of immunological
418 failure. *Immunological reviews* **254**, 54–64 (2013).
- 419 10. Pallikkuth, S., Parmigiani, A., Silva, S. Y., George, V. K., Fischl, M., Pahwa, R. & Pahwa, S.
420 Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the
421 2009 H1N1/09 vaccine. *Blood, The Journal of the American Society of Hematology* **120**, 985–993
422 (2012).
- 423 11. Perreau, M., Savoye, A.-L., De Crignis, E., Corpataux, J.-M., Cubas, R., Haddad, E. K., De Leval,
424 L., Graziosi, C. & Pantaleo, G. Follicular helper T cells serve as the major CD4 T cell compartment
425 for HIV-1 infection, replication, and production. *Journal of Experimental Medicine* **210**, 143–156
426 (2013).
- 427 12. Moir, S. & Fauci, A. S. Insights into B cells and HIV-specific B-cell responses in HIV-infected
428 individuals. *Immunological reviews* **254**, 207–224 (2013).

- 429 13. Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W.,
430 Miller, J. D., Leslie, A. J., DePierres, C., *et al.* PD-1 expression on HIV-specific T cells is associated
431 with T-cell exhaustion and disease progression. *Nature* **443**, 350–354 (2006).
- 432 14. Deeks, S. G., Kitchen, C. M., Liu, L., Guo, H., Gascon, R., Narváez, A. B., Hunt, P., Martin,
433 J. N., Kahn, J. O., Levy, J., *et al.* Immune activation set point during early HIV infection predicts
434 subsequent CD4+ T-cell changes independent of viral load. *Blood* **104**, 942–947 (2004).
- 435 15. Mavigner, M., Cazabat, M., Dubois, M., L’Faqihi, F.-E., Requena, M., Pasquier, C., Klopp, P.,
436 Amar, J., Alric, L., Barange, K., *et al.* Altered CD4+ T cell homing to the gut impairs mucosal
437 immune reconstitution in treated HIV-infected individuals. *The Journal of clinical investigation*
438 **122**, 62–69 (2012).
- 439 16. Lucas, C., Wong, P., Klein, J., Castro, T. B., Silva, J., Sundaram, M., Ellingson, M. K., Mao,
440 T., Oh, J. E., Israelow, B., *et al.* Longitudinal analyses reveal immunological misfiring in severe
441 COVID-19. *Nature* **584**, 463–469 (2020).
- 442 17. Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-
443 Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., *et al.* Robust T cell immunity in convalescent
444 individuals with asymptomatic or mild COVID-19. *Cell* (2020).
- 445 18. Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H.,
446 *et al.* Clinical and immunological features of severe and moderate coronavirus disease 2019. *The*
447 *Journal of clinical investigation* **130** (2020).
- 448 19. Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings,
449 S. A., Sutherland, A., Premkumar, L. & Jadi, R. S. Targets of T cell responses to SARS-CoV-2
450 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell*. ISSN: 0092-8674
451 (2020).
- 452 20. Moderbacher, C. R., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger,
453 S., Abbott, R. K., Kim, C., Choi, J., *et al.* Antigen-specific adaptive immunity to SARS-CoV-2 in
454 acute COVID-19 and associations with age and disease severity. *Cell* (2020).
- 455 21. Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C.,
456 Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., *et al.* Deep immune profiling of COVID-19
457 patients reveals distinct immunotypes with therapeutic implications. *Science* **369** (2020).
- 458 22. Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings,
459 S. A., Smith, D. M., Phillips, E., *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in
460 unexposed humans. *Science* **370**, 89–94 (2020).
- 461 23. Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., *et al.*
462 Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nature medicine*,
463 1–3 (2020).
- 464 24. Chen, Z. & Wherry, E. J. T cell responses in patients with COVID-19. *Nature Reviews Immunology*
465 **20**, 529–536 (2020).
- 466 25. Woodruff, M. C., Ramonell, R. P., Nguyen, D. C., Cashman, K. S., Saini, A. S., Haddad, N. S.,
467 Ley, A. M., Kyu, S., Howell, J. C., Ozturk, T., Lee, S., Suryadevara, N., Case, J. B., Bugrovsky, R.,
468 Chen, W., Estrada, J., Morrison-Porter, A., Derrico, A., Anam, F. A., Sharma, M., Wu, H. M., Le,
469 S. N., Jenks, S. A., Tipton, C. M., Staitieh, B., Daiss, J. L., Ghosn, E., Diamond, M. S., Carnahan,
470 R. H., Crowe, J. E., Hu, W. T., Lee, F. E.-H. & Sanz, I. Extrafollicular B cell responses correlate
471 with neutralizing antibodies and morbidity in COVID-19. *Nature Immunology*. ISSN: 1529-2916.
472 <https://doi.org/10.1038/s41590-020-00814-z> (2020).
- 473 26. Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C., Wang, Z., Cho, A., Agudelo, M., Barnes,
474 C., Finkin, S., Hagglof, T., *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
475 Convalescent Individuals. *bioRxiv* (2020).

- 476 27. Quinlan, B. D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcels, M. S., Luo, G., Li, W.,
477 Zhong, G., *et al.* The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response
478 without antibody-dependent enhancement. *IMMUNITY-D-20-00389* (2020).
- 479 28. Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K.,
480 Kent, S. J., Triccas, J. A. & Davenport, M. P. Neutralizing antibody levels are highly predictive of
481 immune protection from symptomatic SARS-CoV-2 infection. *Nat Med.* ISSN: 1546-170X (Electronic)
482 1078-8956 (Linking). <https://www.ncbi.nlm.nih.gov/pubmed/34002089> (2021).
- 483 29. Earle, K. A., Ambrosino, D. M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P. B., Siber, G. R.,
484 Dull, P. & Plotkin, S. A. Evidence for antibody as a protective correlate for COVID-19 vaccines.
485 *Vaccine* (2021).
- 486 30. Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., *et al.*
487 Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood
488 of SARS-CoV-2 infected patients. *EBioMedicine* **55**, 102763 (2020).
- 489 31. Liu, Y., Du, X., Chen, J., Jin, Y., Peng, L., Wang, H. H., Luo, M., Chen, L. & Zhao, Y. Neutrophil-
490 to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with
491 COVID-19. *Journal of Infection* **81**, e6–e12 (2020).
- 492 32. Zhang, B., Zhou, X., Zhu, C., Song, Y., Feng, F., Qiu, Y., Feng, J., Jia, Q., Song, Q., Zhu, B., *et al.*
493 Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease
494 severity and outcome for patients with COVID-19. *Frontiers in molecular biosciences* **7**, 157 (2020).
- 495 33. Boule, A. *et al.* Risk factors for COVID-19 death in a population cohort study from the Western
496 Cape Province, South Africa. *Clin Infect Dis.* ISSN: 1537-6591 (Electronic) 1058-4838 (Linking).
497 <https://www.ncbi.nlm.nih.gov/pubmed/32860699> (2020).
- 498 34. Geretti, A. M., Stockdale, A. J., Kelly, S. H., Cevik, M., Collins, S., Waters, L., Villa, G., Docherty,
499 A., Harrison, E. M., Turtle, L., *et al.* Outcomes of COVID-19 related hospitalisation among
500 people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective
501 observational study (2020).
- 502 35. Bhaskaran, K., Rentsch, C. T., MacKenna, B., Schultz, A., Mehrkar, A., Bates, C., Eggo, R. M.,
503 Morton, C. E., Bacon, S., Inglesby, P., *et al.* HIV infection and COVID-19 death: population-
504 based cohort analysis of UK primary care data and linked national death registrations within the
505 OpenSAFELY platform. *medRxiv* (2020).
- 506 36. Tesoriero, J. M., Swain, C. E., Pierce, J. L., Zamboni, L., Wu, M., Holtgrave, D. R., Gonzalez,
507 C. J., Udo, T., Morne, J. E., Hart-Malloy, R., Rajulu, D. T., Leung, S. J. & Rosenberg, E. S.
508 COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New
509 York State. *JAMA Netw Open* **4**, e2037069. ISSN: 2574-3805 (Electronic) 2574-3805 (Linking).
510 <https://www.ncbi.nlm.nih.gov/pubmed/33533933> (2021).
- 511 37. Braunstein, S. L., Lazar, R., Wahnich, A., Daskalakis, D. C. & Blackstock, O. J. COVID-19 infection
512 among people with HIV in New York City: A population-level analysis of linked surveillance data.
513 *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*
514 (2020).
- 515 38. Jassat, W., Cohen, C., Tempia, S., Masha, M., Goldstein, S., Kufa, T., Murangandi, P., Savulescu,
516 D., Walaza, S., Bam, J.-L., *et al.* Risk factors for COVID-19-related in-hospital mortality in a high
517 HIV and tuberculosis prevalence setting in South Africa: a cohort study. *The Lancet HIV* (2021).
- 518 39. Huang, J., Xie, N., Hu, X., Yan, H., Ding, J., Liu, P., Ma, H., Ruan, L., Li, G., He, N., *et al.*
519 Epidemiological, virological and serological features of COVID-19 cases in people living with HIV
520 in Wuhan City: A population-based cohort study. *Clinical Infectious Diseases* (2020).
- 521 40. Sigel, K., Swartz, T., Golden, E., Paranjpe, I., Somani, S., Richter, F., De Freitas, J. K., Miotto, R.,
522 Zhao, S., Polak, P., *et al.* COVID-19 and people with HIV infection: outcomes for hospitalized
523 patients in New York City. *Clinical Infectious Diseases* (2020).

- 524 41. Shalev, N., Scherer, M., LaSota, E. D., Antoniou, P., Yin, M. T., Zucker, J. & Sobieszczyk, M. E.
525 Clinical Characteristics and Outcomes in People Living With Human Immunodeficiency Virus
526 Hospitalized for Coronavirus Disease 2019. *Clinical Infectious Diseases* (2020).
- 527 42. Vizcarra, P., Pérez-Elias, M. J., Quereda, C., Moreno, A., Vivancos, M. J., Drona, F., Casado,
528 J. L., Moreno, S., Pérez-Elias, M. J., Fortún, J., *et al.* Description of COVID-19 in HIV-infected
529 individuals: a single-centre, prospective cohort. *The Lancet HIV* (2020).
- 530 43. Stoeckle, K., Johnston, C. D., Jannat-Khah, D. P., Williams, S. C., Ellman, T. M., Vogler, M. A.,
531 Gulick, R. M., Glesby, M. J. & Choi, J. J. *COVID-19 in Hospitalized Adults With HIV in Open*
532 *Forum Infectious Diseases* **7** (2020), ofaa327.
- 533 44. Dandachi, D., Geiger, G., Montgomery, M. W., Karmen-Tuohy, S., Golzy, M., Antar, A. A. R.,
534 Llibre, J. M., Camazine, M., Díaz-De Santiago, A., Carlucci, P. M., Zacharioudakis, I. M., Rahimian,
535 J., Wanjalla, C. N., Slim, J., Arinze, F., Kratz, A. M. P., Jones, J. L., Patel, S. M., Kitchell,
536 E., Francis, A., Ray, M., Koren, D. E., Baddley, J. W., Hill, B., Sax, P. E. & Chow Jeremy,
537 H. I. V.-C. D. 2. (-C.-1. C. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry
538 of Patients with HIV and Coronavirus Disease-19. *Clinical Infectious Diseases* (2020).
- 539 45. Haerter, G., Spinner, C. D., Roider, J., Bickel, M., Krznaric, I., Grunwald, S., Schabaz, F., Gillor, D.,
540 Postel, N., Mueller, M. C., *et al.* COVID-19 in people living with human immunodeficiency virus: a
541 case series of 33 patients. *Infection*, **1** (2020).
- 542 46. Karmen-Tuohy, S., Carlucci, P. M., Zervou, F. N., Zacharioudakis, I. M., Rebick, G., Klein, E.,
543 Reich, J., Jones, S. & Rahimian, J. Outcomes among HIV-positive patients hospitalized with
544 COVID-19. *Journal of acquired immune deficiency syndromes (1999)* (2020).
- 545 47. Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W.,
546 Barnaby, D. P., Becker, L. B., Chelico, J. D., Cohen, S. L., *et al.* Presenting characteristics,
547 comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York
548 City area. *Jama* (2020).
- 549 48. Inciarte, A., Gonzalez-Cordon, A., Rojas, J., Torres, B., de Lazzari, E., de la Mora, L., Martinez-
550 Rebollar, M., Laguno, M., Callau, P., Gonzalez-Navarro, A., Leal, L., Garcia, F., Mallolas, J.,
551 Mosquera, M., Marcos, M. A., Ambrosioni, J., Miro, J. M., Martinez, E. & Blanco, J. L. Clinical
552 characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort
553 of adults living with HIV: a single-center, prospective observational study. *AIDS* **34**, 1775–1780. ISSN:
554 1473-5571 (Electronic) 0269-9370 (Linking). <https://www.ncbi.nlm.nih.gov/pubmed/32773471>
555 (2020).
- 556 49. Hadi, Y. B., Naqvi, S. F. Z., Kupec, J. T. & Sarwari, A. R. Characteristics and outcomes of
557 COVID-19 in patients with HIV: a multicentre research network study. *AIDS* **34**, F3–F8. ISSN:
558 1473-5571 (Electronic) 0269-9370 (Linking). <https://www.ncbi.nlm.nih.gov/pubmed/32796217>
559 (2020).
- 560 50. Hoffmann, C., Casado, J. L., Härter, G., Vizcarra, P., Moreno, A., Cattaneo, D., Meraviglia, P.,
561 Spinner, C. D., Schabaz, F., Grunwald, S., *et al.* Immune deficiency is a risk factor for severe
562 COVID-19 in people living with HIV. *HIV medicine* (2020).
- 563 51. Avelino-Silva, V. I., Miyaji, K. T., Mathias, A., Costa, D. A., de Carvalho Dias, J. Z., Lima, S. B.,
564 Simoes, M., Freire, M. S., Caiaffa-Filho, H. H., Hong, M. A., *et al.* CD4/CD8 ratio predicts yellow
565 fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients. *JAIDS*
566 *Journal of Acquired Immune Deficiency Syndromes* **71**, 189–195 (2016).
- 567 52. Carson, P. J., Schut, R. L., Simpson, M. L., O'Brien, J. & Janoff, E. N. Antibody class and subclass
568 responses to pneumococcal polysaccharides following immunization of human immunodeficiency
569 virus-infected patients. *Journal of infectious diseases* **172**, 340–345. ISSN: 1537-6613 (1995).
- 570 53. Cooper, C., Thorne, A., Klein, M., Conway, B., Boivin, G., Haase, D., Shafran, S., Zubyk, W.,
571 Singer, J., Halperin, S., *et al.* Immunogenicity is not improved by increased antigen dose or booster
572 dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. *PloS one* **6**, e17758
573 (2011).

- 574 54. Fuster, F., Vargas, J. I., Jensen, D., Sarmiento, V., Acuña, P., Peirano, F., Fuster, F., Arab, J. P.,
575 Martinez, F., Soto, S., *et al.* CD4/CD8 ratio as a predictor of the response to HBV vaccination in
576 HIV-positive patients: A prospective cohort study. *Vaccine* **34**, 1889–1895 (2016).
- 577 55. Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S.,
578 Moodley, D., Hanley, S., *et al.* Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B. 1.351
579 Variant. *New England Journal of Medicine* **384**, 1899–1909 (2021).
- 580 56. Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,
581 Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell,
582 B. I., Hanekom, W., Moosa, M. S., Network for Genomic Surveillance in South, A., Team, C.-K.,
583 Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2 from neutralization
584 by convalescent plasma. *Nature* **593**, 142–146. ISSN: 1476-4687 (Electronic) 0028-0836 (Linking).
585 <https://www.ncbi.nlm.nih.gov/pubmed/33780970> (2021).
- 586 57. Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson,
587 B. E., de Oliveira, T., Vermeulen, M., van der Berg, K., Rossouw, T., Boswell, M., Ueckermann, V.,
588 Meiring, S., von Gottberg, A., Cohen, C., Morris, L., Bhiman, J. N. & Moore, P. L. SARS-CoV-2
589 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *Nat Med* **27**, 622–625.
590 ISSN: 1546-170X (Electronic) 1078-8956 (Linking). [https://www.ncbi.nlm.nih.gov/pubmed/](https://www.ncbi.nlm.nih.gov/pubmed/33654292)
591 [33654292](https://www.ncbi.nlm.nih.gov/pubmed/33654292) (2021).
- 592 58. Garcia-Beltran, W. F., Lam, E. C., St Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman,
593 J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., Sigal, A., Schmidt, A. G., Iafate, A. J.,
594 Naranbhai, V. & Balazs, A. B. Multiple SARS-CoV-2 variants escape neutralization by vaccine-
595 induced humoral immunity. *Cell* **184**, 2523. ISSN: 1097-4172 (Electronic) 0092-8674 (Linking).
596 <https://www.ncbi.nlm.nih.gov/pubmed/33930298> (2021).
- 597 59. Hoffmann, M., Arora, P., Groß, R., Seidel, A., Hörnich, B., Hahn, A., Krüger, N., Graichen, L.,
598 Hofmann-Winkler, H., Kempf, A., Winkler, M. S., Schulz, S., Jäck, H., Jahrsdörfer, B., Schrezenmeier,
599 H., Müller, M., Kleger, A., Münch, J. & Pöhlmann, S. SARS-CoV-2 variants B.1.351 and B.1.1.248:
600 Escape from therapeutic antibodies and antibodies induced by infection and vaccination. *bioRxiv*.
601 eprint: <https://www.biorxiv.org/content/early/2021/02/11/2021.02.11.430787.full.pdf>.
602 <https://www.biorxiv.org/content/early/2021/02/11/2021.02.11.430787> (2021).
- 603 60. Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D.,
604 Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha,
605 S., Bhiman, J. N., Bhorat, A. E., du Plessis, J., Esmail, A., Groenewald, M., Horne, E., Hwa,
606 S. H., Jose, A., Lambe, T., Laubscher, M., Malahleha, M., Masenya, M., Masilela, M., McKenzie,
607 S., Molapo, K., Moultrie, A., Oelofse, S., Patel, F., Pillay, S., Rhead, S., Rodel, H., Rossouw,
608 L., Taoushanis, C., Tegally, H., Thombrayil, A., van Eck, S., Wibmer, C. K., Durham, N. M.,
609 Kelly, E. J., Villafana, T. L., Gilbert, S., Pollard, A. J., de Oliveira, T., Moore, P. L., Sigal,
610 A., Izu, A. & Group, N.-S. G. W.-V. C. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine
611 against the B.1.351 Variant. *N Engl J Med*. ISSN: 1533-4406 (Electronic) 0028-4793 (Linking).
612 <https://www.ncbi.nlm.nih.gov/pubmed/33725432> (2021).
- 613 61. Jassat, W., Mudara, C., Ozougwu, L., Tempia, S., Blumberg, L., Davies, M.-A., Pillay, Y., Carter,
614 T., Morewane, R., Wolmarans, M., *et al.* Difference in mortality among individuals admitted to
615 hospital with COVID-19 during the first and second waves in South Africa: a cohort study. *The*
616 *Lancet Global Health* (2021).
- 617 62. Karim, F., Moosa, M., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E.,
618 San, J., Msomi, N., Mlisana, K., Khan, K., Bernstein, M., Manickchand, N., Singh, L., Ramphal,
619 U., Hanekom, W., Lessells, R., Sigal, A. & de Oliveira, T. Persistent SARS-CoV-2 infection
620 and intra-host evolution in association with advanced HIV infection. *medRxiv*. eprint: <https://www.medrxiv.org/content/early/2021/06/04/2021.06.03.21258228.full.pdf>. <https://www.medrxiv.org/content/early/2021/06/04/2021.06.03.21258228> (2021).

- 623 63. Guo, K., Barrett, B. S., Mickens, K. L., Hasenkrug, K. J. & Santiago, M. L. Interferon Resistance
624 of Emerging SARS-CoV-2 Variants. *bioRxiv*. eprint: [https://www.biorxiv.org/content/early/
625 2021/03/21/2021.03.20.436257.full.pdf](https://www.biorxiv.org/content/early/2021/03/21/2021.03.20.436257.full.pdf). [https://www.biorxiv.org/content/early/2021/
626 03/21/2021.03.20.436257](https://www.biorxiv.org/content/early/2021/03/21/2021.03.20.436257) (2021).
- 627 64. Thorne, L. G., Bouhaddou, M., Reuschl, A.-K., Zuliani-Alvarez, L., Polacco, B., Pelin, A., Batra, J.,
628 Whelan, M. V., Ummadi, M., Rojc, A., *et al.* Evolution of enhanced innate immune evasion by the
629 SARS-CoV-2 B. 1.1. 7 UK variant. *bioRxiv* (2021).
- 630 65. Rajah, M. M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Zivaljic,
631 M., Planchais, C., Guivel-Benhassine, F., Porrot, F., Mouquet, H., Chakrabarti, L., Buchrieser, J.
632 & Schwartz, O. B.1.1.7 and B.1.351 SARS-CoV-2 variants display enhanced Spike-mediated fusion.
633 *bioRxiv*. eprint: [https://www.biorxiv.org/content/early/2021/06/11/2021.06.11.448011.
634 full.pdf](https://www.biorxiv.org/content/early/2021/06/11/2021.06.11.448011.full.pdf). <https://www.biorxiv.org/content/early/2021/06/11/2021.06.11.448011> (2021).
- 635 66. Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B. & Gu, X.
636 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:
637 a retrospective cohort study. *The lancet*. ISSN: 0140-6736 (2020).
- 638 67. Van Heerden, A., Barnabas, R. V., Norris, S. A., Micklesfield, L. K., van Rooyen, H. & Celum, C.
639 High prevalence of HIV and non-communicable disease (NCD) risk factors in rural KwaZulu-Natal,
640 South Africa. *Journal of the international AIDS society* **20**, e25012 (2017).
- 641 68. Malaza, A., Mossong, J., Bärnighausen, T. & Newell, M.-L. Hypertension and obesity in adults
642 living in a high HIV prevalence rural area in South Africa. *PloS one* **7**, e47761 (2012).
- 643 69. Federation, I. D. IDF diabetes atlas ninth edition 2019 (2019).
- 644 70. Ryscavage, P., Kelly, S., Li, J. Z., Harrigan, P. R. & Taiwo, B. Significance and clinical management
645 of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. *Antimicrobial
646 agents and chemotherapy* **58**, 3585–3598 (2014).
- 647 71. Sanz, I., Wei, C., Jenks, S. A., Cashman, K. S., Tipton, C., Woodruff, M. C., Hom, J. & Lee,
648 F. Challenges and opportunities for consistent classification of human B cell and plasma cell
649 populations. *Frontiers in immunology* **10**, 2458 (2019).
- 650 72. Khodadadi, L., Cheng, Q., Radbruch, A. & Hiepe, F. The maintenance of memory plasma cells.
651 *Frontiers in immunology* **10**, 721 (2019).
- 652 73. Sauce, D., Almeida, J. R., Larsen, M., Haro, L., Autran, B., Freeman, G. J. & Appay, V. PD-1
653 expression on human CD8 T cells depends on both state of differentiation and activation status.
654 *Aids* **21**, 2005–2013 (2007).
- 655 74. Vollbrecht, T., Brackmann, H., Henrich, N., Roeling, J., Seybold, U., Bogner, J. R., Goebel, F. D.
656 & Draenert, R. Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific
657 CD8 T cells in chronic, untreated HIV-1 infection. *Journal of medical virology* **82**, 358–370 (2010).
- 658 75. Groom, J. R. & Luster, A. D. CXCR3 in T cell function. *Experimental cell research* **317**, 620–631
659 (2011).
- 660 76. Yang, X., Yu, Y., Xu, J., Shu, H., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., *et al.*
661 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan,
662 China: a single-centered, retrospective, observational study. *The Lancet Respiratory Medicine* **8**,
663 475–481 (2020).
- 664 77. Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., Liu, L., Shan, H., Lei, C.-l.,
665 Hui, D. S., *et al.* Clinical characteristics of coronavirus disease 2019 in China. *New England journal
666 of medicine* **382**, 1708–1720 (2020).
- 667 78. Ambrosioni, J., Blanco, J. L., Reyes-Uruena, J. M., Davies, M. A., Sued, O., Marcos, M. A.,
668 Martinez, E., Bertagnolio, S., Alcami, J., Miro, J. M. & Investigators, C. i. H. Overview of SARS-
669 CoV-2 infection in adults living with HIV. *Lancet HIV* **8**, e294–e305. ISSN: 2352-3018 (Electronic)
670 2352-3018 (Linking). <https://www.ncbi.nlm.nih.gov/pubmed/33915101> (2021).

- 671 79. Chen, Z. & Wherry, E. J. T cell responses in patients with COVID-19. *Nature Reviews Immunology*
672 **20**, 529–536 (2020).
- 673 80. Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara,
674 K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., *et al.* Functional SARS-CoV-2-specific
675 immune memory persists after mild COVID-19. *Cell* **184**, 169–183 (2021).

676 Supplementary Data

Supplementary File 1: Summary of case visits

| Timepoint | Visit | Participants |
|--------------------------|--------------|---------------------|
| 1 | Enrollment | 236 (100.0) |
| 2 | DAY 7 | 157 (66.5) |
| 3 | DAY 14 | 139 (58.9) |
| 4 | DAY 21 | 125 (53.0) |
| 5 | DAY 28 | 142 (60.2) |
| 6 | MONTH 3 | 87 (36.9) |
| 7 | MONTH 6 | 72 (30.5) |
| 8 | MONTH 9 | 24 (10.2) |
| Unscheduled visits | - | 4 (1.7) |
| Total case visits | - | 986 |

Supplementary File 2: Timing of enrollment in PLWH and HIV negative participants

| | All Participants | HIV- | HIV+ |
|--|-------------------------|----------------|--------------|
| Median (IQR) days symptom onset to enrollment | 11 (8 – 18) | 11 (8 – 18) | 11 (8 – 18) |
| Median (IQR) days diagnostic swab to enrollment | 8 (5 -14) | 8.5 (5 – 17.5) | 7.5 (5 – 10) |
| Median (IQR) days symptom onset to diagnostic swab | 3 (1 – 6) | 3 (2 – 6) | 3 (1 – 7) |

Supplementary File 3: ART regimen in PLWH as determined by LC-MS/MS

| LC-MS/MS DETERMINED REGIMEN | NUMBER OF PARTICIPANTS (%) |
|---|-----------------------------------|
| EFV based regimen | 41 (44.1) |
| EFV regimen transitioning to DTG regimen | 15 (16.1) |
| NVP/AZT based regimen | 3 (3.2) |
| DTG based regimen | 4 (4.3) |
| LPV/r based regimen | 6 (6.5) |
| ATV based regimen | 3 (3.2) |
| Combination of TFV, FTC, or 3TC only | 5 (5.4) |
| No detectible ART yet record of ART regimen | 5 (5.4) |
| ART naïve | 6 (6.5) |
| Information not available | 5 (5.4) |

Supplementary File 4: Infection wave 1 COVID-19 disease severity by HIV status

| | All (n=153) | HIV- (n= 90, 58.8%) | HIV+ (n=63, 41.2%) | Odds Ratio (95% CI) | p-value[#] |
|--------------------------|------------------------|--------------------------------|-------------------------------|--------------------------------|----------------------------|
| Asymptomatic | 25 (16.3) | 18 (20.0) | 7 (11.1) | 0.5 (0.2 – 1.3) | 0.18 |
| Ambulatory with symptoms | 89 (58.2) | 51 (56.7) | 38 (60.3) | 1.2 (0.6 – 2.2) | 0.74 |
| Supplemental oxygen | 32 (20.9) | 17 (18.9) | 15 (23.8) | 1.3 (0.6 – 2.9) | 0.54 |
| Death | 7 (4.6) | 4 (4.4) | 3 (4.8) | 1.1 (0.3 – 4.5) | >0.99 |

[#]p-value calculated via 2-sided Fisher's Exact test.

Supplementary File 5: Infection wave 2 COVID-19 disease severity by HIV status

| | All (n=83) | HIV- (n= 53, 63.9%) | HIV+ (n=30, 36.1%) | Odds Ratio (95% CI) | p-value [#] |
|--------------------------|---------------|------------------------|-----------------------|-------------------------|----------------------|
| Asymptomatic | 8 (9.6) | 7 (13.2) | 1 (3.3) | 0.2 (<0.1 – 1.5) | 0.25 |
| Ambulatory with symptoms | 39 (47.0) | 29 (54.7) | 10 (33.3) | 0.4 (0.2 – 1.0) | 0.071 |
| Supplemental oxygen | 30 (36.1) | 13 (24.5) | 17 (56.7) | 4.0 (1.6 – 10.4) | 0.005 |
| Death | 6 (7.2) | 4 (7.5) | 2 (6.7) | 0.9 (<0.1 – 4.4) | >0.99 |

[#]p-value calculated via 2-sided Fisher's Exact test.

Supplementary File 6: Comparison between HIV negative participants requiring and not requiring supplemental oxygen

| | All (n=143) | No Supp. O₂ (n=108, 75.5%) | Supp. O₂ (n=35, 24.5%) | Odds Ratio (95% CI) | p-value[#] |
|------------------------------------|------------------------|--|--|--------------------------------|----------------------------|
| Demographics | | | | | |
| Age years, median (IQR) | 49 (35-62) | 46.5 (34-57) | 62 (47-66) | - | 0.002* |
| Comorbidity, n (%) | | | | | |
| Hypertension [§] , n= 142 | 42 (29.4) | 24 (22.2) | 18 (51.4) | 3.7 (1.7 – 8.1) | 0.002 |
| Diabetes | 32 (22.4) | 19 (17.6) | 13 (37.1) | 2.8 (1.2 – 6.4) | 0.021 |
| Obesity [§] , n= 136 | 64 (47.1) | 53 (40.1) | 11 (31.4) | 0.5 (0.2 – 1.1) | 0.11 |
| Active TB | 1 (0.7) | 0 (0.0) | 1 (2.9) | <0.1 (0 – >10) | 0.25 |
| History TB | 3 (2.1) | 1 (0.9) | 2 (5.7) | 6.5 (0.8 – >10) | 0.15 |
| COVID-19 treatment, n (%) | | | | | |
| Corticosteroids | 47 (32.9) | 22 (20.4) | 25 (71.4) | 9.8 (4.1 – >10) | <0.0001 |
| Anticoagulants | 35 (24.5) | 17 (15.7) | 18 (51.4) | 5.7 (2.5 – >10) | 0.0001 |

[#]p-value calculated via 2-sided Fisher's Exact test, except for * which was calculated via Mann-Whitney U test. [§]Not including pregnancy or unable to be measured.

Supplementary File 7: Comparison between PLWH requiring and not requiring supplemental oxygen

| | All (n=93) | No Supp.O ₂ (n= 60, 64.5%) | Supp.O ₂ (n=33, 35.5%) | Odds Ratio (95% CI) | p-value [#] |
|-----------------------------------|---------------|--|--------------------------------------|------------------------|----------------------|
| Demographic characteristic | | | | | |
| Age years, median (IQR) | 41 (35-50) | 40.5 (34-49) | 41 (36-56) | - | 0.295* |
| Comorbidity, n (%) | | | | | |
| Hypertension | 15 (16.1) | 7 (11.7) | 8 (24.2) | 2.4 (0.8 – 7.2) | 0.144 |
| Diabetes | 10 (10.8) | 6 (10.0) | 4 (12.1) | 1.2 (0.3 – 4.5) | 0.739 |
| Obesity [§] , n= 79 | 27 (34.2) | 15 (25.0) | 12 (36.4) | 2.4 (0.9 – 6.4) | 0.125 |
| Active TB | 9 (9.7) | 4 (6.7) | 5 (15.2) | 2.5 (0.7 – 9.3) | 0.272 |
| History TB | 29 (31.2) | 15 (25.0) | 14 (42.4) | 2.2 (0.9 – 5.4) | 0.103 |
| COVID-19 treatment, n (%) | | | | | |
| Corticosteroids | 27 (29.0) | 9 (15.0) | 18 (54.5) | 6.8 (2.6 – >10) | 0.0001 |
| Anticoagulants | 18 (19.4) | 5 (8.3) | 13 (39.4) | 7.2 (2.3 – >10) | 0.001 |

[#] p-value calculated by 2-sided Fisher's Exact test, except for * which was calculated via Mann-Whitney U test. [§]Not including pregnancy or unable to measure.




Figure 1-figure supplement 1: Effect of ART regimen on disease severity. Disease severity scored on a 3 point scale, where 1: asymptomatic, 2: mild, and 3: supplemental oxygen or death.




Figure 1-figure supplement 2: Distribution of CD4 counts by HIV status. Plotted are the CD4 T cell count distributions for HIV negative, HIV ART suppressed, and HIV viremic participants. X-axis is the median CD4 count over all study visits, and y-axis is relative frequency of participants as percentage.




Figure 1-figure supplement 3: Viremia and ART in PLWH requiring versus not requiring supplemental oxygen. (A) HIV viremia was calculated as the number of study timepoints with HIV RNA > 200 copies/ml divided by all measured timepoints for PLWH. (B) The fraction of timepoints with no detectable ART was calculated as the number of study timepoints where the concentration of none of the ART components was above level of quantification divided by all measured PLWH timepoints. No significance for comparison in (A) or (B) as determined by Fisher's Exact test.




Figure 1-figure supplement 4: Dependence of time to SARS-CoV-2 clearance on CD4 count and HIV status. (A) Number of participants remaining SARS-CoV-2 positive by qPCR with time as a function of CD4 count. (B) Number of participants remaining SARS-CoV-2 positive by qPCR with time as a function of HIV status. Time is days post-diagnostic swab. Only participants who were tested with two conclusive tests result (either SARS-CoV-2 positive or negative) during the time-period were included.




Figure 2-figure supplement 1: The differential effect of HIV on the CD4 count and neutrophil to lymphocyte ratio between waves - full dataset and number of data points per plot. (A) The concentration of CD4 T cells in the blood in all participants in all infection waves and at all time-points as a function of disease severity. Disease severity was scored as 1: asymptomatic, 2: mild, and 3: requiring supplemental oxygen and/or death. CD4 counts in PLWH (B) and HIV negative (C) participants in waves 1 versus waves 2 during active SARS-CoV-2 in during active SARS-CoV-2 infection and after SARS-CoV-2 clearance. (D) Neutrophil to lymphocyte ratio (NLR) in the blood in all participants in all infection waves and at all time-points as a function of disease severity. NLR in PLWH (E) and HIV negative (F) participants in waves 1 versus waves 2 during active SARS-CoV-2 in during active SARS-CoV-2 infection and after SARS-CoV-2 clearance. SARS-CoV-2 positive indicates a timepoint where SARS-CoV-2 RNA was detected in the upper respiratory tract. Data shown as violin plots with median and IQR, with the median also denoted below each plot. Fold-change in the second wave versus first wave is indicated by the number above the second wave data, with arrow denoting direction of change. p-values are * <0.05; ** <0.01; *** < 0.001, **** < 0.0001 as determined by Kruskal-Wallis test with Dunn's multiple comparison correction for the left plots or by Mann-Whitney U test for the other data.




Figure 3-figure supplement 1: Gating strategy. (A) Gating of T cell subsets. Live CD3⁺ cells were gated into CD4⁺ and CD8⁺ subsets, which were further divided based on CXCR3, HLA-DR, and PD-1 for CD8 T cells and CXCR3, CCR7, HLA-DR, and PD-1 for CD4 T cells. (B) Gating of B cell subsets. Live CD19⁺ cells were subdivided into memory, naive, and antibody secreting cells (ASC) based on CD27 and CD38. ASC were further subdivided into plasma cells and plasmablasts based on CD138.